Luramax 40 Tablet contains Lurasidone 40 mg, an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar depression. Lurasidone acts primarily by modulating dopamine D2 and serotonin 5-HT2A receptors, contributing to its antipsychotic and mood-stabilizing effects. It is effective in reducing psychotic symptoms such as hallucinations, delusions, and disorganized thinking, as well as improving mood and cognitive function in affected patients. Luramax 40 is administered orally, with dosing individualized based on clinical response and tolerability. Common adverse effects include nausea, somnolence, akathisia, and extrapyramidal symptoms, although it generally exhibits a favorable side effect profile compared to typical antipsychotics. Caution is advised in patients with a history of cardiovascular disease, seizures, or metabolic disorders. Lurasidone should be used under close medical supervision, with regular monitoring of metabolic parameters and mental status. It is contraindicated in patients with known hypersensitivity to the drug and should be avoided during pregnancy unless the potential benefits outweigh the risks. Luramax 40 Tablet offers a valuable therapeutic option for managing complex psychiatric conditions, promoting symptom control and enhancing patient quality of life when integrated into a comprehensive treatment plan.